HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Circulating blood cellular glucose transporters - Surrogate biomarkers for neonatal hypoxic-ischemic encephalopathy assessed by novel scoring systems.

AbstractOBJECTIVE:
We examined Red Blood Cell (RBC) Glucose Transporter isoform 1 (GLUT1) and White Blood Cell (WBC) Glucose Transporter isoform 3 (GLUT3) protein concentrations to assess their potential as surrogate biomarkers for the presence of hypoxic-ischemic encephalopathy (HIE) and response to therapeutic hypothermia (TH), with respect to the neurodevelopmental prognosis.
STUDY DESIGN:
A prospective feasibility study of 10 infants with HIE and 8 age-matched control subjects was undertaken. Following parental consent, blood samples were obtained at baseline before institution of TH (<6 h of life), during TH, at rewarming and post-TH in the HIE group with a baseline sample from the control group. GLUT1 and GLUT3 were measured by Enzyme-linked immunosorbent assay (ELISA) with brain biomarkers, Neuron-Specific Enolase (NSE) and Glial Fibrillary Acidic Protein (GFAP). Novel "HIE-high risk" and "Neurological" scores were developed to help identify HIE and to assess severity and prognosis, respectively.
RESULTS:
RBC GLUT1 concentrations were increased at the baseline pre-TH time point in HIE versus control subjects (p = .006), normalizing after TH (p = .05). An association between GLUT1 and NSE concentrations (which was reflective of the HIE-high risk and the Neuro-scores) in controls and HIE pre-TH was seen (R2 = 0.36, p = .008), with GLUT1 demonstrating 90% sensitivity and 88% specificity for presence of HIE identified by Sarnat Staging. WBC GLUT3 concentrations were low and no different in HIE versus control, and GFAP concentrations trended higher during re-warming (p = .11) and post-TH (p = .16). We demonstrated a significant difference between HIE and controls for both the "HIE-high risk" and the "Neurological" Scores. The latter score revealing the severity of clinical neurological illness correlated with the corresponding RBC GLUT1 (R2 value = 0.39; p = .006).
CONCLUSION:
Circulating RBC GLUT1 concentrations with NSE demonstrate a significant potential in reflecting the severity of HIE pre-TH and gauging effectiveness of TH. In contrast, the low neonatal WBC GLUT3 concentrations make discerning differences between degrees of HIE as well as assessing effectiveness of TH difficult. The HIE-high risk and Neurological scores may extend the "Sarnat staging" towards assessing severity and neuro-developmental prognosis of HIE.
AuthorsLiesbeth V Maggiotto, Monica Sondhi, Bo-Chul Shin, Meena Garg, Sherin U Devaskar
JournalMolecular genetics and metabolism (Mol Genet Metab) Vol. 127 Issue 2 Pg. 166-173 (06 2019) ISSN: 1096-7206 [Electronic] United States
PMID31182397 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2019. Published by Elsevier Inc.
Chemical References
  • Biomarkers
  • GFAP protein, human
  • Glial Fibrillary Acidic Protein
  • Glucose Transporter Type 1
  • Glucose Transporter Type 3
  • SLC2A1 protein, human
  • SLC2A3 protein, human
  • Phosphopyruvate Hydratase
Topics
  • Biomarkers
  • Erythrocytes (metabolism)
  • Feasibility Studies
  • Female
  • Glial Fibrillary Acidic Protein (metabolism)
  • Glucose Transporter Type 1 (metabolism)
  • Glucose Transporter Type 3 (metabolism)
  • Humans
  • Hypoxia-Ischemia, Brain (diagnosis)
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Male
  • Phosphopyruvate Hydratase (metabolism)
  • Pilot Projects
  • Prognosis
  • Prospective Studies
  • Sensitivity and Specificity
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: